ArticleInfectious diseases and therapy2026
Interim Effectiveness of 2025-2026 mRNA-1283 and BNT162b2 COVID-19 Vaccines Against COVID-19-Related Outcomes Among Adults Aged ≥ 65 Years in the United States.
Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe 2025-2026 COVID-19 vaccine season introduced updated formulations targeting the LP.8.1 lineage. This interim analysis assessed absolute vaccine effectiveness (aVE) of mRNA-1283 and BNT162b2 on COVID-19 outcomes in adults aged ≥ 65 years.
methodsThis retrospective study used linked electronic health record and administrative claims data through January 31, 2026. Adults ≥ 65 years who received the mRNA-1283 or BNT162b2 2025-2026 COVID-19 vaccine were matched to unvaccinated individuals. Inverse probability of treatment weighting was applied to each vaccine's matched cohorts to balance covariates. Each vaccine was evaluated independently against its own unvaccinated comparator group. aVE against COVID-19-related hospitalization and medically attended COVID-19 was estimated using Cox proportional hazards models; aVE = 100 × (1 - hazard ratio).
resultsWe identified 233,072 mRNA-1283 recipients and 422,610 BNT162b2 recipients ≥ 65 years. aVE (95% confidence interval [CI]) of mRNA-1283 against COVID-19-related hospitalization and medically attended COVID-19 was 59.3% (39.0%, 72.9%) and 42.0% (35.0%, 48.3%) among adults ≥ 65 years and 66.9% (45.9%, 79.8%) and 50.2% (42.1%, 57.2%) in ≥ 75 years, respectively. The aVE (95% CI) of BNT162b2 against COVID-19-related hospitalization and medically attended COVID-19 was 48.3% (32.4%, 60.5%) and 41.2% (36.2%, 45.8%) in ≥ 65 years and 45.9% (26.0%, 60.4%) and 44.0% (37.8%, 49.6%) in ≥ 75 years, respectively.
conclusionThis study provides the first real-world evidence that mRNA-1283 was associated with protection against COVID-19-related hospitalization and medically attended COVID-19 among vulnerable older adults at highest risk of severe disease. These findings support mRNA-1283 as an important public health tool for reducing the continual burden of COVID-19 in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.